{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Participants with locally advanced or metastatic ALK-positive tumors were to receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.","id":"OG000","title":"ALK-positive Solid Tumors"}],"populationDescription":"PFS was defined as the time from the first dose of alectinib to disease progression or death from any cause and could not be calculated due to an insufficient number of participants with the event.","reportingStatus":"POSTED","timeFrame":"From first dose of alectinib to disease progression or death from any cause, whichever occurs first (up to 5 years)","title":"PFS in Participants With Primary CNS Tumors as Determined by Both BICR and the Investigator Per RANO Criteria","type":"SECONDARY"}